Evidence map›Paper›PMID 40715548›Full record

ArticleScientific reports2025

Longitudinal dynamics of clinical and neurophysiological changes in parkinson's disease over four and a half years.

Estefanía Santana-Román, Emmanuel Ortega-Robles, Oscar Arias-Carrión

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Walking as a Window to the Brain: Redefining Gait in Neurology.Medical sciences (Basel, Switzerland) · 2026
    Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Estefanía Santana-Román *Unidad de Trastornos del Movimiento y Sueño (TMS), Hospital General Dr. Manuel Gea González, Ciudad de México, 14080, México.ORCID http://orcid.org/0009-0000-7901-0444
Emmanuel Ortega-Robles *Unidad de Trastornos del Movimiento y Sueño (TMS), Hospital General Dr. Manuel Gea González, Ciudad de México, 14080, México.ORCID http://orcid.org/0000-0002-1667-2253
Oscar Arias-CarriónUnidad de Trastornos del Movimiento y Sueño (TMS), Hospital General Dr. Manuel Gea González, Ciudad de México, 14080, México. ariasemc2@gmail.com.ORCID http://orcid.org/0000-0002-9982-7571

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is a clinically heterogeneous neurodegenerative disorder whose trajectory is shaped by progressive motor impairment and cortical dysfunction. However, longitudinal studies integrating clinical scales with direct neurophysiological assessments remain scarce. In this 4.5-year cohort study, we conducted one of the longest clinical-electrophysiological follow-ups in PD to date, evaluating 22 patients across early and advanced stages using both Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores and transcranial magnetic stimulation (TMS). We demonstrate that the cortical silent period (CSP), a marker of GABAergic inhibition, progressively lengthens over time and is associated with motor decline, suggesting its potential as a dynamic biomarker of disease progression. Resting motor threshold (rMT) and motor asymmetry also deteriorated longitudinally, with changes most pronounced following the COVID-19 pandemic-suggesting that environmental stressors may accelerate PD pathophysiology. Unlike prior short-term studies, our findings reveal persistent cortical reorganization over several years, independent of sex, and underscore the clinical relevance of TMS-derived metrics in tracking disease progression. These findings suggest that CSP may serve as a non-invasive and scalable biomarker for monitoring Parkinson's disease progression and informing neurophysiological endpoints in future therapeutic studies.

Indexed as

Parkinson DiseaseAgedBiomarkersCOVID-19Disease ProgressionEvoked Potentials, MotorFemaleHumansLongitudinal StudiesMaleMiddle AgedMotor CortexTranscranial Magnetic StimulationBiomarkersDisease progressionLongitudinal studyMotor asymmetryParkinson’s diseaseTranscranial magnetic stimulation

Identifiers

PMID40715548
PMCPMC12297360

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.